Distinct Parameters in the EEG of the PLP α-SYN Mouse Model for Multiple System Atrophy Reinforce Face Validity by Lorenz Härtner et al.
ORIGINAL RESEARCH
published: 10 January 2017
doi: 10.3389/fnbeh.2016.00252
Frontiers in Behavioral Neuroscience | www.frontiersin.org 1 January 2017 | Volume 10 | Article 252
Edited by:
Nuno Sousa,
University of Minho, Portugal
Reviewed by:
Chong Shen,
University of Colorado Boulder, USA
Stefano Bastianini,





Received: 11 April 2016
Accepted: 27 December 2016
Published: 10 January 2017
Citation:
Härtner L, Keil TWM, Kreuzer M,
Fritz EM, Wenning GK, Stefanova N
and Fenzl T (2017) Distinct Parameters
in the EEG of the PLP α-SYN Mouse
Model for Multiple System Atrophy
Reinforce Face Validity.
Front. Behav. Neurosci. 10:252.
doi: 10.3389/fnbeh.2016.00252
Distinct Parameters in the EEG of the
PLP α-SYN Mouse Model for Multiple
System Atrophy Reinforce Face
Validity
Lorenz Härtner 1, Tobias W. M. Keil 1, Matthias Kreuzer 2, Eva Maria Fritz 1,
Gregor K. Wenning 3, Nadia Stefanova 3 and Thomas Fenzl 1*
1Department of Pharmacology and Toxicology, Institute for Pharmacy, Leopold-Franzens University of Innsbruck, Innsbruck,
Austria, 2Neuroanesthesia Laboratory, Atlanta Veterans Affairs Medical Center/Emory University and Department of
Anesthesiology, Emory University, Atlanta, Georgia, 3Department of Neurology, Medical University Innsbruck, Innsbruck,
Austria
Multiple system atrophy (MSA) is a neurodegenerative movement disorder characterized
by parkinsonian symptoms and cerebellar symptoms. Sleep disturbances also play a
crucial role in MSA. One of the most convincing animal models in MSA research is the
PLP α-SYN model, but to date no studies on sleep disturbances in this mouse model,
frequently found in MSA patients are available. We identified spectral shifts within the
EEG of the model, strikingly resembling results of clinical studies. We also characterized
muscle activity during REM sleep, which is one of the key symptoms in REM sleep
behavioral disorder. Spectral shifts and REM sleep-linked muscle activity were age
dependent, supporting Face Validity of the PLP α-SYN model. We also strongly suggest
our findings to be critically evaluated for Predictive Validity in future studies. Currently,
research on MSA lacks potential compounds attenuating or curing MSA. Future drugs
must prove its potential in animal models, for this our study provides potential biomarkers.
Keywords: multiple system atrophy, sleep, EEG, mouse model, predictive validity
INTRODUCTION
Multiple system atrophy (MSA) is a sporadic and rapidly progressive neurodegenerative movement
disorder characterized by parkinsonian (MSA-P) symptoms and cerebellar symptoms (MSA-C)
(Gilman et al., 2008; Fanciulli and Wenning, 2015). Non-motor features including autonomic and
sleep disturbances also play a crucial role in MSA that significantly reduce patients’ quality of
life. Epidemiologic studies report a disease probability of 0.6–3/100.000 patients per year (Bower
et al., 1997). The mean disease onset is around 60 years and both sexes are affected equally
with less than 9 years survival time after onset (Schrag et al., 2008; Kuzdas et al., 2013). Ethnic
differences exist in the expression of the motor sub-forms. In Europe, MSA-P prevails in 58% of
cases reported (Geser et al., 2006) and in North America 60% of MSA patients develop MSA-
P symptoms (May et al., 2007). In contrast to that, more than 83% of reported MSA cases are
diagnosed as MSA-C in Japan (Yabe et al., 2006). Currently, symptomatic treatment is restricted
to autonomic and parkinsonian features (Papatsoris et al., 2008). On a neuropathological level,
neurodegeneration affects multiple brain areas including the basal ganglia, cerebellum, pontine,
and inferior olivary nuclei, pyramidal tract, intermediolateral cell column, and Onuf ’s nucleus. The
neuronal degeneration is often accompanied by gliosis (Wenning et al., 2004). MSA is also classified
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among the α-synucleinopathies because of α-synuclein (αSYN)-
immunoreactive inclusion bodies in oligodendrocytes, so-called
glial cytoplasmic inclusions (GCI) (Wenning et al., 2008).
Intriguingly, sleep disturbances, as described below are
common in MSA patients affecting sleep regulation at multiple
levels, reflecting the diffuse underlying neuropathological
processes involved in MSA (Ghorayeb et al., 2002). Disturbances
of sleep include insomnia, excessive daytime sleepiness (EDS),
restless legs syndrome, rapid eye movement sleep (REMS),
behavior disorder (RBD), sleep related breathing disorders
and nocturnal inspiratory stridor. On polysomnographic
examination, MSA patients show disturbed sleep architecture
including sleep fragmentation and REMS behavior disorder,
including REMS without atonia (REM-A) (Wetter et al., 2000;
Vetrugno et al., 2004).
RBD is a parasomnia characterized by a loss of normal
skeletal muscle atonia during REMS (REM-A, based on the
nomenclature by Olson and Schenck (Olson et al., 2000; Schenck
et al., 2002; Schenck and Mahowald, 2002). REM-A is a
polysomnographic finding and if combined with nightmares
(of mostly violent content) and dream enactment behavior,
REM-A is referred to as RBD. Among all etiologies RBD is
most common in MSA. In fact, the frequency of RBD is
0.05% among the general population, however, virtually every
MSA patient suffers from RBD (Plazzi et al., 1997; Tachibana
et al., 1997; Vetrugno et al., 2004; Scaglione et al., 2005), first
described by Tison et al. (1995). RBD is frequently the first non-
motor manifestation of neurodegenerative α-synucleinopathies
(Schenck and Mahowald, 1996; Boeve et al., 1998; Iranzo et al.,
2006; Claassen et al., 2010). The first study to document the
relationship of RBD and neurodegenerative diseases reported
that in almost 40% of patients with isolated, idiopathic RBD, it
was accompanied by α-synucleinopathy within a 10-year period
(Schenck and Mahowald, 1996). This finding was confirmed by
several longitudinal investigations in other RBD cohorts (Iranzo
et al., 2006; Postuma et al., 2009), linking RBD as an early risk
factor to the development of α-synucleinopathies (Arnulf, 2012).
Interestingly, two recent studies demonstrated that in contrast
to the waking state, movements during RBD were comparably
fast without tremor and bradykinesia, providing an insight into
motor control during REMS (De Cock et al., 2007, 2011). We
know of only one case report in the literature investigating the
longitudinal course of MSA-RBD (Tachibana and Oka, 2004).
The study demonstrated that RBD related behavior decreased
over time and disease duration, whereas the percentage of REM-
A increased.
Restless leg syndrome (RLS) is a common neurological disorder
that is accompanied by periodic limb movements in sleep (PLMS),
which can be observed in up to 88% ofMSA patients (Plazzi et al.,
1997; Wetter et al., 2000; Vetrugno et al., 2004; Ghorayeb et al.,
2005). RLS is characterized by an unpleasant restlessness, mostly
in the legs associated with an urge to move (Trenkwalder, 1998),
worst at rest, relieved by attempts to move, and most disturbing
in the evenings (Allen et al., 2003).
Sleep fragmentation is a further very common sleep-related
disturbance among MSA patients (Ghorayeb et al., 2002). Sleep
fragmentation is manifested by in an increased number of short
arousals or awakenings and a deficiency in consolidated sleep.
It occurs during periods of non-rapid eye movement sleep
(NREMS) and especially in Parkinson’s Disease also in REMS
(Högl et al., 1998).
The animal model for MSA in the present study: Several
approaches for MSA animal models exist in mouse and rat,
including lesions of nigrostriatal brain regions, injections of
toxins, transgenic models or combinations of these individual
techniques (Stefanova et al., 2005a). One of the most convincing
animal models in present research is the so-called PLP α-SYN
model, a PLP (proteo-lipid-protein promotor) α-synuclein
mouse strain (Kahle et al., 2002). Immunohistochemical
and microscopic studies revealed concordant pathology
between human and murine probes at a cellular level. Hyper-
phosphorylated α-SYN was found in MSA patients and
transgenic mice, the inclusions were similarly half-moon-
or triangulated-shaped and present in the cytosol around
the nucleus. The α-SYN was detergent insoluble, which is a
diagnostic criterion for α-synucleiopathies (Kahle et al., 2002).
Behavioral phenotyping performed with this animal model
revealed coherence with key symptoms of MSA in humans:
Urodynamic analysis showed a less efficient and unstable bladder
activity with an increased voiding contraction amplitude, a
higher frequency of non-voiding contractions and an increased
post-void residual volume (Boudes et al., 2013). Other non-
motor symptoms were a decreased heart rate variability (Kuzdas
et al., 2013) and respiratory dysfunction (Flabeau et al., 2014).
The PLP α-SYN model also showed shorter stride length, deficits
on pole rod and beam walking tests as well as changes in grip
strength and gait variability (Stefanova et al., 2005a,b).
However, the present animal model may not reflect the entire
pathology of human MSA. Especially the temporal distribution
of neuronal degeneration and neuronal loss in relevant brain
regions (Stefanova and Wenning, 2015) may be different. This
may also be true at the behavioral level. So far no studies were
performed to characterize sleep disturbances in the PLP α-SYN
model, common in MSA patients. Potential candidates of sleep
disturbances in the animal model could be RBD with REM-A,
RLS or sleep fragmentation. On one hand, such findings would
strengthen Face Validity for the PLP α-SYN model. On the other
hand, if sleep disturbances would develop longitudinally along
the life span of the animal model, such behavioral manifestations
could serve to establish Predictive Validity for drug screenings
and evaluation of therapeutic approaches.
MATERIALS AND METHODS
Animal Numbers
Male transgenic homozygous mice overexpressing human a-
synuclein under the proteolipid protein (PLP) promotor (the
generation and characterization of the mice has been previously
described in detail (Kahle et al., 2002) and further referred to
as PLP-aSYN or MSA mice) and age-, sex-, and background-
matched wildtype C57BL/6 (control) mice were used in this
study. The control group consisted of 8 mice at an age of 11–
18 weeks (mean BL6young = 14 weeks/±SEM = 1.03) and
8 mice at an age of 38–49 weeks 8 (mean BL6adult = 40.83
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/±SEM = 1.70). The MSA group consisted of 8 mice at an
age of 14–18 weeks (mean MSAyoung = 16/±SEM = 0.46) and
10 mice at an age of 38–49 weeks (mean MSAadult = 45.40
/±SEM = 0.73). No significant age differences were detected
in MSAyoung vs. BL6younganimals (t-test, P = 0.085). We had
to exclude two BL6adult mice as well as one BL6young animal
from our analysis due to low EMG signal quality during signal
processing for REM-A analysis. All transgenic mice (number
of backcrossing over 50) were homozygous. Before transferred
to the laboratory, the animals were genotyped for α-syn by
tail clip PCR using following primers with a product size of
450 bp: fwd: 5′-ATG GATGTATTCATGAAAGG-3′; rev: 5′-TTA
GGCTTCAGGTTCGTAG-3′ (Kahle et al., 2002).
Housing Conditions
After transferring the mice from the animal facility to the
laboratory, we placed each animal in an individual home cage
(custom made) with access to water and food ad libitum.
Throughout the study two home cages were always kept in a
custom made sound attenuated chamber (olfactory and visual
contact). We allowed the animals to adapt to the day/night
cycle of the experiments (lights ON: 10 a.m./lights OFF: 10
p.m.; temperature: 23◦C ± 1◦C) for 7 days before implantation
of the recording electrodes, followed by a 14 day recovery
period. During recovery, we permanently kept two animals in
individual home cages in an electrically shielded (bench top
Faraday cage, Peabody, USA) and sound attenuated recording
chamber (custom made). We connected each animal to a pre-
amplifier (amplification: 1x, npi electronics, Tamm, Germany) to
allow for adaption 3 days before we started the chronic recordings
that typically lasted 3 consecutive days (Fenzl et al., 2007). After
termination of the experiment we sacrificed the animals by
perfusion with 4% PFA and stored the brains at−80◦C for further
analyses.
Surgical Procedure
We anesthetized the animals with 1.9–2.2% isoflurane at a
flow rate of 200ml/min (U-410, agnthos, Lidingö, Sweden). A
feedback-controlled heating pad kept the body temperature at
37.8◦C (cma450, Harvard Apparatus, USA). At a sufficient level
of anesthesia we fixated the animals in a stereotaxic frame,
shaved the head, opened the scalp medially, and removed the
periosteum. We used a dental precision driller (Typ 4911, KaVo,
Germany) to drill six holes into the skull and drove two Jeweler’s
screws (diameter: 150µm) in the median two holes to fixate
the implantations. The EEG electrodes were placed in the left
and right part of the frontal bone (from Bregma/rostral: +1
mm, medio-lateral: ±1 mm) and the grounding and reference
electrode in the parietal bone (from Bregma/caudal: −2.5 mm,
medio-lateral: ±1.8mm). Two EMG electrodes were lowered
bilaterally into the neck muscle, directly caudal to the occipital
bone. All recording electrodes, consisting of gold wire (diameter:
150µm, Häfner, München, Germany) with ball-shaped endings
were soldered to a PCP socket board (Type 861-87-008-10-
001101, preci-dip, Switzerland), which was later connected to the
pre-amplifier and the recording cable. For a detailed description
of the surgical procedure and electrode design, please refer
to Fulda et al. (2011) and Polta et al. (2013). During and
after surgery, animals received analgesic treatment (Meloxicam,
0.5mg/ml suspension, s.c. injection and 5 × 10−4 mg/ml for 7
days in drinking water).
Data Recording and Processing
We attached the pre-amplifiers to the socket boards, mounted
on each animal’s head and to a commutator (SL-10, Dragonfly,
Ridgeley, USA), which was mounted on a weight-neutral swivel
system (custom made, Streicher M., Innsbruck, Austria) to allow
the animal free movement in all three dimensions during the
chronic recording sessions (video monitored). We recorded for
23 h in one session and used hour 24 for animal care and housing
maintenance before starting the next recording session. Each
recorded channel was individually amplified (amplifier type:
DPA-2FL, npi electronics, Tamm, Germany), band-pass filtered
(amplifier-hardware filter before digitization: 0.1–100Hz for EEG
and 50–90 Hz for EMG/gain: 1000x), and sampled with 250
Hz (POWER1301-1, CED, Cambridge, Great Britain). We used
Spike2 Software (Version 7, CED, Cambridge, Great Britain) to
record and store the digitized data. We applied a semi-automated
sleep scoring software developed by the authors (Kreuzer et al.,
2015) to assign the vigilance statesWAKE, NREMS, and REMS to
non-overlapping 4 s EEG episodes (1 epoch = 4 s). This analysis
software is based on algorithms published for sleep analysis in
rats (Louis et al., 2004), adapted for mice (Fenzl et al., 2007).
A scorer blind to the data sets manually reviewed all semi-
automated sleep scorings at epoch-level. We only considered
epochs of a defined vigilance state that lasted longer than 3 epochs
(12 s) for a change in the behavioral status. Consequently, we
attributed vigilance changes that lasted shorter than three epochs
only to micro arousals within the EEG.
Data Analysis
We analyzed the EEG data of the single animals in multiple
ways. For an overall impression of the animal’s sleep behavior,
we present the proportions of the different vigilance states
WAKE, NREMS, and REMS for the experimental groups (BL
\6: young and adult; MSA: young and adult). Then we derived
the mean duration each animal spent in any given vigilance
state (bout length) to gain quantitative and qualitative insight
in the fragmentation of vigilance states in the experimental
groups. Additionally we analyzed the number of transitions
between the vigilance states in each experimental group with five
possible transitions between WAKE, NREMS, and REMS (the
transition from WAKE to REMS is behaviorally not present).
We also analyzed spectral parameters of the EEG [e.g., power
spectral density (PSD)] to detect qualitative differences in the
EEG properties of the experimental groups. For that we down-
sampled the EEG recorded at 250–125Hz and estimated the
power spectral density for non-overlapping 4 s episodes with the
MATLAB pwelch function. Additionally the “Slow wave activity”
(SWA-PSD: 0.5–5Hz) during NREMS was evaluated. In a last
step, we searched manually at epoch-level for the occurrence
of REM-A episodes (REMS episodes where the animal clearly
expressed EMG activity).
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REM-A Analysis
We defined REMS without atonia (REM-A) as a single epoch
or multiple epochs of REMS with simultaneous neck muscle
activity, recorded from the EMG electrodes. For that, we re-
analyzed the corresponding EMG activity for each single REMS
epoch identified by the semi-automatic sleep scoring and/or
manual re-scoring. The re-analysis was necessary to detect REM-
A epochs/episodes that were scored as WAKE during the semi-
automatic process of sleep scoring due to EMG-activity which is
defined asWAKE per se in our scoring routines (Fenzl et al., 2007,
2011; Polta et al., 2012; Kreuzer et al., 2015). We only assigned
muscle activity to REM-A if the EEG could be unmistakably
discriminated from an WAKE EEG (different scorers blind to
each other and to the data sets).
Statistical Analysis
For the comparison of the sleep behavior between the MSA
and the control animals we used two-way repeated ANOVA
tests (SigmaStat 3.5, Systat, Erkrath, Germany). The factors were
“strain” and “time.” We further used two-way repeated ANOVA
tests with factors “age” and “time” to evaluate the impact of
age on the sleep behavior within the strain. We further used
this statistical test to check for differences in the SWA spectral
power with factors “age” and “time.” For the evaluation of
possible differences in the power spectral density between the
groups at different vigilance levels, we used a two-way ANOVA
with Bonferroni correction. Our post-hoc test of choice was the
Bonferroni correction to correct for multiple comparisons (p
< 0.05). We applied the concept of cumulative probability to
the bout length analysis and used the two sample Kolmogorov-
Smirnov test to check for differences between the distributions
of bout lengths (MATLAB R2015a, MathWorks, Natick, Ma,
USA). We further used the two sample Kolmogorov-Smirnov
test with Bonferroni correction to evaluate possible difference
in state transition probabilities. In order to evaluate differences
in REM-A among the groups and to evaluate the separating
performance of REMS amount (Figures 1C,F) using Youden’s
index, we performed an area under the receiver operating curve
(AUC) analysis including 95% confidence intervals [95% ci; AUC
values adjusted to the interval (0.5–1)]. We performed these
tests using the MATLAB-based MES toolbox (Hentschke and
Stüttgen, 2011) with the following considerations: AUC > 0.64
a medium effect and AUC> 0.71 a strong effect (Rice and Harris,
2005).
All experiments were performed in accordance with
the international and national guidelines and were
approved by the “Bundesministerium für Wissenschaft,
Forschung und Wirtschaft, Austria (BMWFW-66-008/0011-





The circadian distribution of sleep and WAKE in MSA and
control animals represented a typical distribution of the vigilance
states WAKE, NREMS, and REMS, as expected for nocturnal
animals (Figure 1). During the inactive period (lights on), both
groups showed low levels of WAKE, that strongly increased in
the active period (lights off). Consequently, we observed high
(low) proportions of NREMS in the inactive (active) period. We
observed this distribution of vigilance states in all four groups
(Figures 1A–E). The distribution of the WAKE proportions over
24 h was significantly different in the young animals (ANOVA: p
= 0.015) with a significantly higher proportion ofWAKE directly
before turning the lights off in the BL\6 mice (Figure 1A). We
found no difference between the old BL\6 and old MSA mice
(Figure 1D). We further observed differences in the NREMS
proportions in the young mice (ANOVA: p = 0.015; Figure 1B),
but not in the aged animals (Figure 1E). We found a significantly
different distribution of REMS in the young animals (ANOVA: p
< 0.001) with significantly higher amounts of REMS in young
MSA animals during the inactive period (Figure 1C). ROC
analysis of REMS amounts, averaged over the inactive period
revealed an AUC of 0.80 (95% ci: 0.51–1) with a sensitivity =
0.71 and a specifity = 0.86 at the maximum Youden’s index.
We also found a difference in REMS distribution in the aged
animals (ANOVA: p = 0.002), but the post-hoc analysis revealed
an increased REMS only during the 12th h.
Intra-group Analysis
The circadian distribution of WAKE and NREMS changed
in both animal groups during aging to some degree
(Figures 2A,B,D,E). These differences were present in the
control group only during the active period (Figures 2D,E),
while MSA animals could be differentiated also during the
inactive period (Figures 2A,B). Seniors of both animal
groups spent more time in NREMS during the active
period. Clearly, old MSA mice spent less time in REMS
during the inactive period, when compared with young
animals of the same group (Figure 2C). We found no
differences between young and old control animals for REMS
(Figure 2F).
Inter/Intra-group Analysis/Bout Length
We found some differences in the distribution of the bout
lengths, i.e., how long the animals remained in a vigilance
state once they entered it. During the active period, the young
MSA animals had a different distribution of WAKE bouts than
young BL\6 or aged MSA mice (Kolmogorov-Smirnov: p =
0.002 vs. young BL\6; p = 0.001 vs. aged MSA). Aged BL\6
animals expressed a significantly different distribution of NREMS
bouts during the inactive period. (Kolmogorov-Smirnov: p =
0.002 vs. young BL\6; p < 0.001 vs. young MSA; p = 0.001
vs. aged MSA). Figure 3 displays the cumulative distribution




We only observed significant differences in the transition
frequency between vigilance states in the inactive period and
only between aged BL\6 and young MSA animals. During the
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FIGURE 1 | Age-matched sleep behavior in MSA mice vs. control animals. (A,B,D,E) WAKE and NREMS is generally very similar in young MSA mice and young
control animals (FWake = 5.997, p = 0.015; FNREMS = 5.997, p = 0.015) and adult (FWake = 0.0000768, p = 0.993; FNREMS = 0.321, p = 0.572). (C,F) Significant
differences between MSA mice and control animals in REMS, detected around 10 (F = 17.336, p < 0.001) clearly decrease in adult mice (F = 10.397, p = 0.002).
For all graphs shown: X-axis represents the experimental time of one 24 h-recording session, Y-axis represents the amount of the behavioral state WAKE, NREMS,
and REMS. White background: inactive period/lights on (hour 0 to hour 12), gray background: active period/lights off (hour 12 to hour 24). All data are 2 h means ±
SEM, Two way ANOVA, followed by Bonferroni corrections (p ≤ 0.05). Number of animals: nMSAyoung = 8, nMSAadult = 10, nControlyoung = 8, nControladult = 6.
inactive period the animals showed an increased proportion of
transitions between NREMS and REMS as compared to the active
period, where the animals predominantly transitioned between
WAKE and REMS. The corresponding bubble plots in Figure 4
display the detailed transitioning behavior of all four animal
groups.
REMS Latency
While both control groups expressed coherent REMS not before
around 2000 epochs into the active period (ca. 130 min after the
transition from light to dark), both MSA groups showed REMS
directly after the transition from light to dark. Additionally, we
only found this phenomenon during the active period, while
during the inactive period REMS latency was not different among
all four animal groups (please refer to Supplementary Figures 1, 2
for details).
Spectral Analysis
We analyzed the spectral power from the bandpass-filtered
EEG signals (δ, θ, α, µ, β bands) and found most significant
differences for WAKE during the active period (Figure 5A), for
the slow wave activity (SWA: 0.5–5 Hz) in NREMS in the inactive
period (Figure 5B) and for REMS during the inactive period
(Figure 5C). Young MSA mice had significantly increased levels
of spectral power almost across the whole frequency band. This
was found for young MSA against old MSA mice (hash marks)
and for young MSA mice against young control mice (asterisks).
We found no such differences for young vs. old control animals.
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FIGURE 2 | Longitudinal sleep behavior in MSA mice and BL6 control animals. (A,B) Young MSA mice have significant differences in WAKE (F = 0.0118, p =
0.914) and NREMS (F = 0.272, p = 0.602) in the inactive period (hour 10) and the active period (hour 18), when compared with adult MSA animals. (C) Although, only
significant at hour 2 and hour 10, the overall REMS behavior implicates behavioral differences in REMS in adult MSA animals vs. young MSA mice during the inactive
period (F = 6.161, p = 0.014). (D,E) Similar to MSA mice, control animals have significant differences in WAKE (F = 5.955, p = 0.016) (hour 16) and NREMS (F =
7.947, p = 0.006) (hour 12 and hour 16). (F) No differences could be detected for control mice during REMS (F = 7.947, p = 0.006). For all graphs shown: X-axis
represents the experimental time of one 24 h-recording session, Y-axis represents the amount of the behavioral state WAKE, NREMS, and REMS. White background:
inactive period/lights on (hour 0 to hour 12), gray background: active period/lights off (hour 12 to hour 24). All data are 2 h means ± SEM, Two way ANOVA, followed
by Bonferroni corrections (p ≤ 0.05). Number of animals: nMSAyoung = 8, nMSAadult = 10, nControlyoung = 8, nControladult = 6.
Importantly, no differences could be detected between old MSA
animals and both control groups (Figure 5A). The increase of
power in the second half of the θ-band and the first half of the
α-band in young MSA mice was attenuated and shifted to the
left covering only the θ-band in old MSA mice and both control
groups. During SWA, young MSA mice had decreased power
between 1 and 2 Hz, followed by increased power between 3 and
5 Hz, when compared to all other animal groups. No differences
in spectral parameters were detected in old MSA, young and
old control animals (Figure 5B). During REMS, we found no
differences between all four groups within the δ-band with the
exception at 1 Hz. Here the frequency power of young MSA
mice was significantly below values from old MSA and young
control animals. For the in REMS dominantly present frequency
band around 8–10 Hz (θ, α band), young MSA mice significantly
showed increased power, compared to old MSA (hash marks)
and young control animals (asterisks, Figure 5C). In contrast
to WAKE active, the frequency power in the µ- and-β band of
young MSA animals was only significantly increased to old MSA
animals and not to both control groups.
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FIGURE 3 | Cumulative probability plots of the pooled data containing the bout lengths in the different vigilance states during active and inactive
periods. (A,B) Only in the active period (lights off, B), young MSA mice showed a different distribution of WAKE bout length in comparison to adult MSA and young
BL\6 animals. Here the young MSA animals had higher probability of WAKE episodes of long duration. Adult MSA mice tend to have shorter WAKE episodes in the
active period. (C,D) During the inactive period (lights on, C), the distribution of NREMS bout length in adult control animals was significantly different to all other
groups, with an increased probability of longer NREMS episodes (two sample Kolmogorov Smirnov test with Bonferroni correction (full circles); empty circles: p <
0.05). No significant differences could be detected during REMS, although during the active period data were not as consistent as during the inactive period.
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FIGURE 4 | Vigilance state transition diagrams in the active and inactive period. The four experimental groups are represented by the colored circles. The
circle size corresponds to the probability of the state transition occurring (gray arrows), derived from pooled data. Purple connector lines between the circles indicate
significant differences in the distribution of the transition (two sample Kolmogorov Smirnov test with Bonferroni correction).
REM-A in MSA Animals
We detected small amounts of REM-A in 3 out of 7 young BL\6
and 4 out of 6 aged BL\6 mice. The maximum proportion of
REM-A episodes was 12% in the young and 7% in the aged BL\6
group (percentage of REM-A in the total amount of REMS). In
the MSA group, 6 out of 8 young and 8 out of 10 aged mice
expressed REM-A with maximum proportions of 22% (young)
and 69% (aged). The AUC analysis revealed that REM-A is
strongly and significantly increased in the aged MSA animals
when compared to young (AUC: 0.83; 95% Ci: 0.61–1) and old
(AUC: 0.82; 95% Ci: 0.58–1) BL\6 mice. Figure 6 shows the
occurrence and proportion of REM-A for each individual animal
of all four experimental groups. Please refer to Supplementary
Figure 3 for raw EEG- and EMG-recordings showing REM-A.
DISCUSSION
The development of MSA is commonly accompanied by
sleep impairments such as disturbed sleep architecture, sleep
fragmentation, RBD, and EDS, but there has been no sleep-
related investigation of this neurodegenerative disorder in animal
models of MSA, so far. Here, we describe the presence of
several sleep impairments in the PLP α-SYN model for the first
time. Furthermore, the expression of sleep impairments clearly
correlated with age in mice, which strongly consolidates Face
Validity in the PLP α-SYN model. Hence, we recommend to
use the age-related sleep impairments as potential biomarkers to
establish Predictive Validity with the present mouse model. We
believe that our findings can contribute to future substance and
drug screenings for MSA treatment.
Sleep Architecture
The general sleep/wake behavior of our young control animals
(Figures 1, 2) is in accordance with previous findings in
the literature on WAKE, NREMS, and REMS distribution in
C57BL/6J mice (Tobler et al., 1997) and in C57BL/6N mice
(Polta et al., 2013). Our old control mice expressed increased
amounts of NREMS at the beginning of the active period, when
compared to the young animals of the same group. Previous work
on sleep patterns in adolescent mice revealed increased amounts
of NREMS [postnatal P60-119, (Nelson et al., 2013)], while
total sleep remained constant. Nelson and co-workers further
described decreased REMS in early adolescence. We could not
find such changes in REMS in our control animals, probably due
to the age difference between the animals Nelson and co-workers
used and the animals from our study. Additionally, the animals
used by our colleagues were YFP-H mice, that have a (C57BL/6J
× CBA) F1 background (Jackson, 2016). No comparative sleep
analyses have been performed between these two lines so far.
To our knowledge only very few studies used aged mice in
EEG studies so far. Silvani and co-workers for example recorded
from hypocretin-deficient narcoleptic mice aged 10–11 month
and found several changes in the sleep architecture (Silvani et al.,
2014) between transgenic and control mice. But the study did
not perform longitudinal EEG-recordings as performed in the
present experiments.
Our control animals fit into the well-established picture of
general sleep/wake behavior of mice. A comparison of the control
animals with young and old MSA mice revealed no fundamental
differences in WAKE and NREMS (intergroup comparison,
Figure 1). As the genetic background of the PLP α-SYN model is
the C57BL/6 breeding line (Kahle et al., 2002) we did not expect
differences but performed these comparisons to ensure validity of
our results.
The amount of REMS in old MSA mice was comparable
to REMS levels of young and old control animals. This is in
agreement with clinical findings on normal amounts of REMS
in MSA patients (Vetrugno et al., 2004; Stanzani-Maserati et al.,
2014). But old MSA animals spent significantly less amount in
REMS than the young MSA mice. These differences in NREMS
may be attributed to the differentiated expression of the disease
with age. The significantly increased amounts of REMS in the
young MSA animals have the potential to function as an early
biomarker before other symptoms develop, at least in the PLP
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FIGURE 5 | Distribution of the power of distinct frequency bands in the
EEG of MSA animals and control animals. (A) The power spectrum of the
recorded EEGs, subdivided into distinct frequency bands (δ, θ, α, µ, β) is
significantly increased in young MSA animals, compared to all three other
animal groups. Clearly in adult MSA mice, the power spectrum approached
values of the young and adult control groups. The young and adult control
groups can hardly be distinguished. ANOVA: MSAyoung vs. controlyoung: Fδ =
6.032, p = 0.015; Fθ = 186,668, p < 0.001; Fα = 232,338, p < 0.001; Fµ
=252,450, p < 0.001; Fβ = 21.779, p < 0.001. MSAyoung vs. MSAadult: Fδ
= 39.451, p < 0.001; Fθ = 252.690, p < 0.001; Fα = 392.296, p < 0.001;
Fµ = 545.561, p < 0.001; Fβ = 720.189, p < 0.001. (B) During slow wave
activity (SWA, δ-band) from 0.5 to around 2 Hz the power of the EEG in young
MSA mice is below values of all three other animal groups, while from
3 to 5 Hz the EEG-power of young MSA animals is constantly above values of all
(Continued)
FIGURE 5 | Continued
other groups. ANOVA: MSAyoung vs. controlyoung: Fδ = 1.023, p = 0.314;
Fθ = 29,887, p < 0.001; Fα = 37,524, p < 0.001; Fµ = 39,634, p < 0.001;
Fβ = 69.349, p < 0.001. MSAyoung vs. MSAadult: Fδ = 5.637, p = 0.019; Fθ
= 99.557, p < 0.001; Fα = 157.661, p < 0.001; Fµ = 280.615, p < 0.001;
Fβ = 440.146 p < 0.001. (C) The EEG-power of the relevant frequency band
for REMS is constantly above values from all other groups. #: MSA young vs.
MSA adult; *: MSA young vs. control mice young. All data are 0.5 Hz means ±
SEM, Two way ANOVA, followed by Bonferroni corrections (p ≤ 0.05). Number
of animals: nMSAyoung = 8, nMSAadult = 10, nControlyoung = 8, nControladult
= 6. ANOVA: MSA young vs. control young: Fδ = 1.208, p = 0.274; Fθ =
51,050, p < 0.001; Fα = 17,819, p < 0.001; Fµ = 6961, p = 0.009; Fβ =
13.377, p < 0.001. MSAyoung vs. MSAadult: Fδ = 0.456, p = 0.501; Fθ =
96.382, p < 0.001; Fα = 201.180, p < 0.001; Fµ = 454.495, p < 0.001;
Fβ = 438.324, p < 0.001.
FIGURE 6 | Muscle activity during REMS in MSA mice and control
animals. The figure presents the proportion of REM-A. Each bar represents
an individual animal within the experimental group. A “0” marks an individual
animal without REM-A. We had to exclude one animal from the BL\610week
group because of artifacts distorting the EEG. The animals in the control group
expressed little REM-A in contrast to the MSA group. Especially the adult MSA
animals showed high proportions of REM-A episodes. AUC analysis revealed
strong and significant differences between the animals from the MSAadult
group and both BL\6 groups.
α-SYN mouse model, although further investigations are needed
to reveal its strength. At present the use of this biomarker as
a prodromal marker to the clinical situation is tempting, but is
not applicable before the occurrence of early risk-factors such as
RBD in patients. Around 50% of patients with idiopathic RBD are
going to develop a synucleinopathy such as Parkinson’s disease
(PD), dementia, or MSA (Postuma et al., 2013).
The addition of observed elevated levels of REMS to the
list of biomarkers at early stages of RBD-diagnosis may bear
the potential to improve early diagnosis and to differentiate
between developing synucleinopathies. Therefore, we suggest
to add increased REMS to the list of other markers awaiting
confirmation, as reviewed by Postuma et al. (2013). Elevated
REMS in young MSA animals may as well serve as Predictive
Validity for future drug screenings, as potential substances for
treatment could reduce REMS to levels of control animals (and
patients).
When compared with obstructive sleep apnea (OSA) patients,
the sleep architecture of MSA patients is characterized by
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increased NREMS stages 1 and 2 and decreased NREMS stages
3 and 4 (Vetrugno et al., 2004) (Note: In present clinical sleep
research, the NREMS stages 3 and 4 are now summarized in
NREMS stage 3, Iber et al., 2007). In humans, NREMS stage 2
is mainly characterized by sleep spindles, while NREMS stage
3 is defined by the presence of dominant slow wave activity
(Iber et al., 2007) (see also discussion below). In mice, sleep
spindles per se are well defined (Vyazovskiy et al., 2004; Kim
et al., 2012) but to date this criterion is not established yet
to differentiate between individual sleep stages of NREMS in
mice. So the differences in NREMS stage 1, stage 2 and stage
3 (stage 4) of MSA patients should not be used as parameters
to establish sleep-related Face Validity in the PLP α-SYN
model.
REMS latency seems to be decreased in MSA patients (Manni
et al., 1993; Plazzi et al., 1997; Stanzani-Maserati et al., 2014).
We also found decreased REMS latency in our MSA animals,
compared to both control groups. We are aware that mice are
nocturnal, polyphasic sleepers, facts hampering the transfer of
clinical findings on shorter REMS latency to our results. So
rather than supporting Face Validity of the PLP α-SYN mouse
model for REMS latency, shorter REMS latency during the active
period in mice may correlate to EDS sleepiness in humans
diagnosed for MSA or PD (Ghorayeb et al., 2005; Moreno-
López et al., 2011). This hypothesis is additionally supported
by the fact that old MSA mice had significantly shorter WAKE
bout lengths (coherent period of WAKE) in the active period
(Figure 3B).
Data derived from a comparison of all possible transitions
between the different vigilance states remained elusive, when all
four groups of animals were compared (Figure 4). During the
inactive period, only the young MSA animals were significantly
different to the old control groups. At the moment we
neither can connect this to distinct animal sleep/wake behavior,
nor did we find an explanation in the clinical literature
on MSA.
Spectral Analysis
We did not find different EEG PSD properties in the entire
spectrum between young and old control animals for any
vigilance state. During active WAKE (Figure 5A), the PSD of
young MSA mice was higher at most frequencies compared to
the old MSA mice and both control groups. Our results obtained
from young MSA mice (Figures 5A,C) agree with findings from
clinical studies. Patients diagnosed with iRBD expressed similar
patterns of increased spectral power in the δ- and θ-band during
WAKE and REMS (Fantini et al., 2003;Massicotte-Marquez et al.,
2008; Iranzo et al., 2010; Brayet et al., 2015). In these clinical
studies this spectral shift was a feature particularly observed
- in patients that developed neurodegenerative disorders later
on. The study of Iranzo and co-workers describes increased
power in all frequency bands during WAKE and REMS, with
most prominent shifts in the θ-band of patients developing mild
cognitive impairments (MCI) (Iranzo et al., 2010). But in order
to compare EEG signals from humans and mice, there are three
critical aspects to consider: (1) The cortical topography is largely
different. Additionally, the strongest frequency shifts described
in the clinical studies were observed from central and frontal
regions.We recorded EEG signals only from one electrode placed
above the medio-frontal region of the mouse cortex. (2) EEG
signals from single channel recordings in humans and mice may
not be comparable on a one to one basis, because the size of
the neuronal network generating the signal may be different. (3)
The frequency range definition for the classical frequency bands
varies for mouse and human EEG. (Note that even particular
frequency bands named identically in human and murine EEGs
contain partly different corner frequencies of the bandpass filter).
Despite these differences we believe that the frequency shifts
during the development of MSA-like symptoms strengthen Face
Validity in the PLP α-SYN mouse model due to its similarity to
clinical findings. Furthermore, we believe that these frequency
shifts, as well as the mentioned increased amounts of REMS
bear the potential to establish Predictive Validity with a mouse
model for MSA for the first time. In our model, we would expect
a potential treatment initiated at an early stage of the diseases
to cause a shift of spectral power and/or REMS to baseline
values. This assumption may be valid in other animal models
for various other neurodegenerative diseases as well. Human
studies linked an increase of spectral power in the δ- and θ-
band and a shift of the frequency spectrum not only to RBD
(as a precursor of MSA), but also to PD, Lewy body dementia
(LBD) (Massicotte-Marquez et al., 2008) and Alzheimer’s disease
(Brayet et al., 2015). The PLP α-SYN mouse model may
further be of use to investigate future treatment approaches to
reduce MSA symptoms. Old PLP α-SYN mice receiving the
treatment should show changes in their PSD back to levels of
young MSA mice.
Our analysis of the SWApower revealed higher SWApower in
youngMSA animals than in the old ones and both control groups
during the inactive period, indicating higher sleep intensity in
the young animals (Figure 5B, 3–5Hz). As sleep is regulated
as a function of preceding WAKE (Borbély et al., 1981; Tobler
and Borbely, 1986; Trachsel et al., 1986), SWA in particular
serves as an index of sleep intensity (Franken et al., 1991). High
levels of SWA may mirror increased sleep pressure in young
MSA mice. It could also represent higher physical activity during
preceding WAKE in young MSA mice. Lower levels of SWA
could indicate lower overall sleep quality in old MSA mice. The
lower SWA power may be coherent with clinical findings, where
Parkinsonian patients showed lower sleep efficiency with disease
progression (Diederich et al., 2005).
REMS with Muscle Activity
REM-A, a lack of muscle atonia during REMS is one of the
cardinal symptoms of RBD (Olson et al., 2000; Boeve et al., 2007;
Boeve, 2010; Mccarter et al., 2012). This phenomenon, reported
for 80–90% of MSA patients (Ghorayeb et al., 2002, 2005; De
Cock et al., 2011) was also present in 80% of the old MSA mice
(Figure 6). We also observed first signs of REM-A in youngMSA
mice that were not as manifested as in the old MSA group.
To our knowledge, only one article described REMS without
atonia in mice so far (Brooks and Peever, 2011). The authors
could show that transgenic mice with an impaired GABAA-
and glycine-receptor function exhibit the full spectrum of RBD
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symptoms including muscle activity during REMS.While Brooks
and Peever analyzed the EMG signal in arbitrary 5 s epochs after
processing the raw signal (Brooks and Peever, 2011), we always
linked our 4 s EMG epochs (RMS-filtered) to its corresponding
4 s EEG epoch during analysis. This EEG/EMG linkage is based
on a series of algorithms which decide in a first step between
WAKE and sleep per se due to EMG activity in each 4-s epoch
(Fenzl et al., 2007; Kreuzer et al., 2013, 2015). In a second
step each previously scored sleep-state epoch is analyzed in the
spectral and temporal domains of the EEG trace. This ensures a
precise discrimination between quiet WAKE and sleep. Finally,
all sleep-state epochs are analyzed in the spectral and temporal
domains to discriminate between NREMS and REMS in each
4 s epoch (Kreuzer et al., 2015). In the present study REM-
A was evaluated by manually rescoring each individual epoch
assigned to REMS and each individual epoch originally assigned
to WAKE which was flanked by at least three consecutive REMS
epochs without muscle activity. Interestingly, our non-arbitrary
approach and the approach applied by other authors (Brooks
and Peever, 2011) closely resemble the clinical situation of
MSA and/or RBD, supporting the appearance of REM-A in two
different animal models.
Our procedure of scoring REM-A as described in the methods
section may bear a subjectivity bias that we tried to overcome by-
blinded scoring from two scorers. The use of neck muscle activity
only to detect REM-Amay hold some limitation when comparing
potential REM-A inmice with clinical findings on REM-A during
RBD, which includes more widespread body movements. Hence,
further studies including a precise video analysis of mice during
REMS are necessary.We further found a low proportion of REM-
A in some of the control animals from both age groups. This
could be a phenomenon which is also present in C57BL/6N
mice and was so far excluded due to semi-automated scoring
methods that automatically forbid muscle activity during REMS
by default. Hence, REM-A episodes would have been missed
by excluding this erroneous WAKE through manual re-scoring.
This REM-A episodes in the controls may also be due to the
mentioned subjective bias. But then, the subjectivity in blind re-
scoring would account for all four experimental groups. So we are
confident that occurrence of REM-A inmice can be established to
strengthen Face Validity and Predictive Validity in the PLP α-SYN
mouse model.
Concluding Remarks
The general sleep analysis of the PLP α-SYN mouse model
for MSA revealed sleep impairments that have been described
clinically. The change of spectral properties observed in the
mouse model for MSA also agreed with results of studies
conducted in humans. We further observed the phenomenon
of REM-A, one of the key symptoms of RBD, in the animal
model. Most important, the change in spectral properties
as well as in REM-A probability was age dependent in
the PLP α-SYN mouse model. Our data strengthen face
validity of the PLP α-SYN model. The next step should be
a critical evaluation for potential Predictive Validity in future
studies.
Currently, research on MSA lacks potential compounds
attenuating the course of or even curing the disease. Our findings
may present an important step toward a valid animal model
for future drug development. The described age dependency of
REMS, the changes in the PSD, and the occurrence of REM-A
episodes may have strong potential to serve as biomarkers for
drug effects.
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